key: cord-0869671-s5h47wc6
authors: Kaomongkolgit, Ruchadaporn; Sawangarun, Wanlada
title: Oral lichen planus following mRNA COVID‐19 vaccination
date: 2022-03-22
journal: Oral Dis
DOI: 10.1111/odi.14182
sha: 291105c05f7c354f38e0a6f93fce2471a18dee7d
doc_id: 869671
cord_uid: s5h47wc6

nan

In the global pandemic of COVID-19, vaccines have played a pivotal role in managing the outbreak and are administered globally (Samaranayake et al., 2021) . The SARS-CoV-2 mRNA vaccine BNT162b2 (Pfizer/BioNTech) is a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor-binding domain of the SARS-CoV-2 spike protein (Samaranayake et al., 2021) .

Recently, reports demonstrated the association of BNT162b2 vaccination and lichen planus (LP) (Herzum et al., 2021; Hiltun et al., 2021; Merhy et al., 2021; Piccolo et al., 2022) . Here, we report a case of oral lichen planus (OLP) following the administration of the BNT162b2 vaccine. To our knowledge, this side effect has not been reported elsewhere. Lichen planus is a T-cell-mediated inflammatory disease involving mucocutaneous, and its pathogenesis is unclear. However, vaccineinduced LP is reported in hepatitis B, influenza, or herpes zoster vaccinations (Lai & Yew, 2017) . Therefore, for COVID-19 vaccination, it might be possible which the underlying mechanism as autoimmune development triggered by epitope. Another possible mechanism is vaccine-associated hyperviscosity (Mungmunpuntipantip & Wiwanitkit, 2021) .

Although OLP has been reported in the COVID-19-vaccinated patients (Troeltzsch et al., 2021; Sharda et al., 2022; Kulkarni & Sollecito, 2021) , including the present case report, there is no definitive evidence demonstrating a direct link between COVID-19 vaccines and OLP. Further observations will be validated to confirm whether this condition is genuinely related to the vaccine or coincidental and to explore the precise underlying mechanism.

However, the continuation of the vaccination campaign could lead to an increase in reports of OLP. Therefore, healthcare providers F I G U R E 1 Image of the right buccal mucosa (a) and the left buccal mucosa (b) showing papular and reticular white striae; image of the dorsal tongue (c) and the ventral tongue (d) showing plaque-like OLP manifestations

Lichen planus flare following COVID-19 vaccination: A case report

Lichen planus arising after COVID-19 vaccination

COVID-19 vaccination: Possible short-term exacerbations of oral mucosal diseases

Lichen planus and lichenoid drug eruption after vaccination

New-onset cutaneous lichen planus triggered by COVID-19 vaccination

COVID-19 vaccination and lichen planus

COVID vaccine-induced lichen planus on areas previously affected by vitiligo

Coronavirus disease 2019 (COVID-19) vaccines: A concise review

Development of oral lichen planus after COVID-19 vaccination -A rare case report

Oral lichen planus following the administration of vector-based COVID-19 vaccine (Ad26.COV2.S). Oral Diseases